期刊文献+

活动性强直性脊柱炎患者外周血MIF、IL-23、RANKL、OPG和DKK1检测的临床意义 被引量:8

Clinical significance of detection of MIF,IL-23,RANKL,OPG and DKK1 in peripheral blood of patients with active ankylosing spondylitis
下载PDF
导出
摘要 目的探讨活动性强直性脊柱炎(ankylosing spondylitis,AS)患者外周血巨噬细胞移动抑制因子(MIF)、白细胞介素-23(IL-23)、核因子κB受体活化因子配体(RANKL)、骨保护素(OPG)、Dickkopf-1(DKK1)检测的临床意义。方法选取2013年2月至2016年1月风湿免疫科住院并治疗的AS患者46例为观察组,另选取同期行体检健康者38例为对照组。观察组于入院首日清晨空腹经肘静脉采集血,对照组取体检血样,检测2组外周血中MIF、IL-23、RANKL、OPG、DKK1水平,以及ESR及CRP水平,并进一步分析观察组外周血MIF、IL-23、RANKL、OPG、DKK1水平与疾病活动的相关性。结果观察组外周血MIF(25.38±11.05)ng/ml、IL-23(374.90±38.19)pg/L、RANKL(21.53±17.44)pg/ml、OPG(5.04±1.65)pg/ml、DKK1(0.71±0.16)ng/ml水平均高于对照组的(4.02±0.83)ng/ml、(179.82±21.76)pg/L、(7.62±1.24)pg/ml、(1.89±0.32)pg/ml、(0.13±0.04)ng/ml,差异均有统计学意义(P<0.01);观察组患者外周血ESR(40.25±29.79)mm/h及CRP(4.78±3.40)mg/L水平显著高于对照组的(8.27±0.49)mm/h、(2.61±0.35)mg/L,差异均有统计学意义(P<0.01)。相关分析结果显示:观察组患者外周血MIF、IL-23、OPG含量均与疾病活动因子ESR、CRP水平呈正相关(P<0.05),RANKL、DKK1与疾病活动因子ESR、CRP水平无明显相关性(P>0.05)。结论活动性强直性脊柱炎患者外周血中MIF、IL-23、RANKL、OPG、DKK1水平显著上升,且MIF、IL-23、RANKL上升幅度与疾病活动性呈正相关,借此可对疾病的严重度及治疗效果做出客观评估。 Objective To investigate the clinical significance of detection of macrophage migration inhibitory factor( MIF),interleukin-23( IL-23),receptor activator of nuclear factor kappa B ligand( RANKL),osteoprotegerin( OPG),Dickkopf-1( DKK1) in peripheral blood of patients with active ankylosing spondylitis( AS). Methods Forty-six patients with AS who were admitted and treated in our hospital from February 2013 to January 2016 were enrolled as observation group,at the same time,the other 38 healthy subjects were enrolled as control group. The blood specimens were collected in patients of both groups,then the levels of MIF,IL-23,RANKL,OPG,DKK1,ESR and CRP in peripheral blood of patients were detected,moreover,the correlation between the levels of these indexes and disease activity was analyzed. Results The levels of MIF( 25. 38 ± 11. 05) ng/ml,IL-23( 374. 90 ± 38. 19) pg/L,RANKL( 21. 53 ± 17. 44) pg/ml,OPG( 5. 04 ± 1. 65) pg/ml,DKK1( 0. 71 ± 0. 16) ng/ml in observation group were significantly higher than those in control group( 4. 02 ± 0. 83) ng/ml,( 179. 82 ± 21. 76) pg/L.( 7. 62 ± 1. 24) pg/ml,( 1. 89 ± 0. 32) pg/ml,( 0. 13 ± 0. 04) ng/ml,respctively( P〈0. 01).Moreover the levels of ESR( 40. 25 ± 29. 79) mm/h and CRP( 4. 78 ± 3. 40) mg/L in observation group were also significantly higher than those in control group( 8. 27 ± 0. 49) mm/h,( 2. 61 ± 0. 35) mg/L,respectively( P〈0. 01). The correlation analysis results showed that the levels of MIF,OPG,IL-23 in observation group were positively correlated to those of ESR,CRP( P〈0. 05),however,the levels of RANKL and DKK1 were not correlated with those ESR and CRP( P〉0. 05).Conclusion The levels of MIF,IL-23,RANKL,OPG,DKK1 in peripheral blood of patients with active ankylosing spondylitis are obviously increased,moreover,the increase degree of MIF,IL-23,RANKL is positively correlated to disease activity,thereby,which can evaluate the severity of disease and therapeutic effects objectively.
出处 《河北医药》 CAS 2018年第2期178-182,共5页 Hebei Medical Journal
基金 河北省保定市科学技术研究与发展计划(编号:16ZF141)
关键词 强直性脊柱炎 MIF IL-23 RANKL OPG DKK1 检测意义 ankylosing spondylitis MIF IL-23 RANKL OPG DKK1 detection significance
  • 相关文献

参考文献6

二级参考文献31

  • 1古洁若,张汉伟,赵丽珂,黄烽,颜光美,余得恩.基质金属蛋白酶-3在强直性脊柱炎中的作用和意义探讨[J].中国药物与临床,2004,4(4):270-276. 被引量:14
  • 2柴本甫,汤雪明,李慧.骨折二期愈合过程中的成纤维细胞成骨作用[J].中华骨科杂志,1996,16(4):245-248. 被引量:33
  • 3中华中医药学会.中医内科常见病诊疗指南:西医疾病部分[M].北京:中国中医药出版社,2008:55-56.
  • 4Vander Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria [J]. Arthritis Rheum, 1984, 27(4): 361-368.
  • 5Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity lndex[J]. J Rheumator, 1994, 21(12).. 2286- 2291.
  • 6Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS)[J]. Rheumatorogy (Oxford), 2006, 45(10): 1197-1200.
  • 7中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:54-58.
  • 8Zochling J, Braun J, van der Heijde D. Assessments in ankylosing spondylitis [J ]. Best Pract Res Clin Rheumatol, 2006, 20.. 521-537.
  • 9Pincus T, Askanase A D, Swearingen C J. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases [J]. Rheum Dis Clin North Am, 2009, 35: 819-827.
  • 10Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society ( ASAS ) handbook: a guide to assess spondyloarthritis[J]. Ann Rheum Dis, 2009, 68(Suppl 2):ii1-ii44.

共引文献85

同被引文献83

引证文献8

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部